228 related articles for article (PubMed ID: 16855830)
1. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease.
Fujita Y; Ohama E; Takatama M; Al-Sarraj S; Okamoto K
Acta Neuropathol; 2006 Sep; 112(3):261-5. PubMed ID: 16855830
[TBL] [Abstract][Full Text] [Related]
2. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
[TBL] [Abstract][Full Text] [Related]
3. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
5. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
6. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
7. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
8. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
9. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
10. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
11. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
14. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.
Braak H; Sastre M; Del Tredici K
Acta Neuropathol; 2007 Sep; 114(3):231-41. PubMed ID: 17576580
[TBL] [Abstract][Full Text] [Related]
15. Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.
Parkkinen L; O'Sullivan SS; Collins C; Petrie A; Holton JL; Revesz T; Lees AJ
J Parkinsons Dis; 2011; 1(3):277-86. PubMed ID: 23939308
[TBL] [Abstract][Full Text] [Related]
16. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.
Ryu MY; Kim DW; Arima K; Mouradian MM; Kim SU; Lee G
J Neurol Sci; 2008 Mar; 266(1-2):9-12. PubMed ID: 17884098
[TBL] [Abstract][Full Text] [Related]
17. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
[TBL] [Abstract][Full Text] [Related]
18. Fragmentation of the Golgi complex of dopaminergic neurons in human substantia nigra: New cytopathological findings in Parkinson's disease.
Tomás M; Martínez-Alonso E; Martínez-Martínez N; Cara-Esteban M; Martínez-Menárguez JA
Histol Histopathol; 2021 Jan; 36(1):47-60. PubMed ID: 33078843
[TBL] [Abstract][Full Text] [Related]
19. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
20. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
Wakabayashi K
Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
